Track Phase 2 & Phase 3 clinical trial catalysts driving biotech stock movements
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients β’ Fda approval
Biocon Biologics UK Ltd is conducting a Phase 3 clinical trial evaluating PERT-IJS plus trastuzumab, carboplatin and docetaxel for the treatment of HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Prostate CA β’ Fda approval
BicycleTx Limited is conducting a Phase 3 clinical trial evaluating Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy for the treatment of Prostate CA. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Diabetes β’ Fda approval
Gan & Lee Pharmaceuticals. is conducting a Phase 3 clinical trial evaluating GZR4 for the treatment of Diabetes. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Schizophrenia β’ Fda approval
Karuna Therapeutics is conducting a Phase 3 clinical trial evaluating Xanomeline and Trospium Chloride Capsules for the treatment of Schizophrenia. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Eosinophilic Granulomatosis With Polyangiitis β’ Fda approval
Guangdong Hengrui Pharmaceutical Co., Ltd is conducting a Phase 3 clinical trial evaluating SHR-1703 for the treatment of Eosinophilic Granulomatosis With Polyangiitis. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
SCN2A Encephalopathy β’ Fda approval
Praxis Precision Medicines is conducting a Phase 3 clinical trial evaluating PRAX-562 for the treatment of SCN2A Encephalopathy. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Myopia β’ Topline data
Ann & Robert H Lurie Children's Hospital of Chicago is conducting a Phase 2 clinical trial evaluating Atropine for the treatment of Myopia. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Pulmonary Hypertension β’ Topline data
Key Phase 2 catalyst for Insmed
Postsurgical Pain β’ Primary endpoint
Dalin Tzu Chi General Hospital is conducting a Phase 3 clinical trial evaluating Sebacoyl Dinalbuphine Ester for the treatment of Postsurgical Pain. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Hospital Acquired Pneumonia β’ Primary endpoint
Nantes University Hospital is conducting a Phase 3 clinical trial evaluating Dexamethasone for the treatment of Hospital Acquired Pneumonia. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Neonatal Sepsis β’ Primary endpoint
Post Graduate Institute of Medical Education and Research, Chandigarh is conducting a Phase 3 clinical trial evaluating Methylene Blue for the treatment of Neonatal Sepsis. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Breast Cancer β’ Primary endpoint
Gustave Roussy, Cancer Campus, Grand Paris is conducting a Phase 3 clinical trial evaluating GRCC-Investigational for the treatment of Breast Cancer. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Stage 0 Bladder Urothelial Carcinoma β’ Primary endpoint
SWOG Cancer Research Network is conducting a Phase 3 clinical trial evaluating BCG Solution for the treatment of Stage 0 Bladder Urothelial Carcinoma. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Kidney Stone β’ Primary endpoint
University Hospital Tuebingen is conducting a Phase 3 clinical trial evaluating Furosemide 40 mg for the treatment of Kidney Stone. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Persistent Corneal Epithelial Defect β’ Topline data
University of Illinois at Chicago is conducting a Phase 2 clinical trial evaluating Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome for the treatment of Persistent Corneal Epithelial Defect. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Stage III Cutaneous Melanoma AJCC v7 β’ Topline data
National Cancer Institute (NCI) is conducting a Phase 2 clinical trial evaluating Dabrafenib Mesylate for the treatment of Stage III Cutaneous Melanoma AJCC v7. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Breast Cancer β’ Topline data
Beth Israel Deaconess Medical Center is conducting a Phase 2 clinical trial evaluating Fulvestrant for the treatment of Breast Cancer. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Non Small Cell Lung Cancer β’ Topline data
FundaciΓ³n GECP is conducting a Phase 2 clinical trial evaluating Ipilimumab for the treatment of Non Small Cell Lung Cancer. The primary completion date is March 2026, which represents a key catalyst for the company. This trial enrolls 100 patients.
Sign up to create watchlists, get alerts, and access detailed catalyst analysis powered by AI.